Tagraxofusp: a promising agent for the treatment of pediatric BPDCN

Recent advances in the treatment of BPDCN & the long-term benefits of tagraxofuspПодробнее

Tagraxofusp: a breakthrough therapy in BPDCNПодробнее

Pediatric BPDCN and Use of Tagraxofusp in ChildrenПодробнее

Clinical trials investigating tagraxofusp in BPDCN and beyondПодробнее

The promise of CD123-targeted therapy in BPDCNПодробнее

Pivotal Phase 2 trial data for tagraxofusp in BPDCNПодробнее

Insights into a study evaluating tagraxofusp for the treatment of BPDCNПодробнее

The safety and efficacy of tagraxofusp for the treatment of BPDCNПодробнее

Frontline treatment in BPDCN & the best route to allogeneic transplantationПодробнее

Tagraxofusp for BPDCN gives encouraging resultsПодробнее

Major breakthroughs in BPDCN treatmentПодробнее

Managing patients with transplant-ineligible BDPCN with tagraxofuspПодробнее

Blastic Plasmacytoid Dendritic Cell NeoplasmПодробнее

Advances in BPDCNПодробнее

Blastic plasmacytoid dendritic cell neoplasms: current and future treatment optionsПодробнее

The current landscape of treatment for BPDCNПодробнее

Tagraxofusp demonstrates anti-tumor activity without myelosuppression in patients with BPDCNПодробнее

Tagraxofusp: from BPDCN to other myeloid malignanciesПодробнее

ELZONRIS® (tagraxofusp-erzs) Mechanism of Action in BPDCNПодробнее